Back
ESC Premium Access

State of the Art - SGLT2 inhibitors in cardiovascular disease

Session: New frontiers: SGLT2 inhibitors in cardiorenal disease
Topic: Risk Factors and Prevention
Speaker: Professor M. Sabatine (Boston, US)
Event: ESC Congress 2019

Congress Presentation

About the speaker

Professor Marc Sabatine

Brigham And Women'S Hospital, Harvard Medical School, Boston (United States of America)
23 presentations
1 follower

4 more presentations in this session

Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58

Speaker: Doctor T. Zelniker (Vienna, AT)

Access
Abstract
Slides
Video
Thumbnail

Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Speaker: Doctor J. Udell (Toronto, CA)

Access
Abstract
Slides
Video
Thumbnail

SGLT-2 inhibitors versus GLP-1 receptor agonists and risk of mortality, chronic kidney disease and hospitalisation for heart failure in patients with type 2 diabetes

Speaker: Doctor C. Noergaard (Aalborg, DK)

Access
Abstract
Slides
Video
Thumbnail

Integrating SGLT2 inhibitors in diabetes treatment: a guide for cardiologists

Speaker: Professor N. Sattar (Glasgow, GB)

Access
Slides
Video
Thumbnail

Access the full session

New frontiers: SGLT2 inhibitors in cardiorenal disease

Speakers: Professor M. Sabatine, Doctor T. Zelniker, Doctor J. Udell, Doctor C. Noergaard, Professor N. Sattar
Access
Thumbnail

About the event

Image

ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb